ADVERTISEMENT
Ivonescimab Projected to Treat EGFR-TKI Resistant, Advanced NSCLC
A phase 3 trial of the novel immuno-oncology drug ivonescimab, a PD-1/VEGF bispecific antibody (AK112), combined with chemotherapy is underway for patients with locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) with an epidermal growth factor (EGFR) mutation failed after EGFR-tyrosine kinase inhibitor (TKI) treatment.
The randomized, double-blind clinical trial will enroll 320 patients to evaluate the efficacy and safety of ivonescimab combined with pemetrexed plus carboplatin versus placebo combined with pemetrexed plus carboplatin.
The primary endpoint of the trial is progression-free survival (PFS).
Ivonescimab has demonstrated antitumor immune responses and inhibits tumor angiogenesis. Due to the immunosuppressive effect of the overexpressed VEGF in the tumor microenvironment, researchers predict the synergistic anti-tumor effect of anti-PD-1-antibody and anti-VEGF antibody can be realized with ivonescimab.
Further, ivonescimab with chemo for the treatment of EGFR-TKI resistant NSCLC is expected to achieve improved clinical efficacy and safety in comparison to other standard therapies.
In previous international studies, ivonescimab demonstrated good safety and tolerability in the treatment of various subtypes of lung cancer, including NSCLC and small cell lung cancer (SCLC), with excellence anti-tumor effects. A phase 3 clinical trial for the first-line treatment of extensive SCLC with ivonescimab is underway.—Alexa Stoia
Akeso Doses First Patient in the Phase III Trial of Ivonescimab Combined With Chemotherapy in EGFR-TKI Resistant EGFR Mutation Advanced Non-Squamous Non-Small Cell Lung Cancer. News release. PR Newswire; January 30, 2022. Accessed February 4, 2022. https://www.prnewswire.com/news-releases/akeso-doses-first-patient-in-the-phase-iii-trial-of-ivonescimab-combined-with-chemotherapy-in-egfr-tki-resistant-egfr-mutation-advanced-non-squamous-non-small-cell-lung-cancer-301471270.html
